Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_661b3ea63e73acc96731eb73625b1bc2 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-314 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
filingDate |
2007-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06aa05d9fcdad52ddbfe6fdd9ad2cbcb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84699776c8d588f1008b1bdd5a6a936d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17b8c8c04fcbedd86324dbcdf7723a52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9228cab7cb2a462bfd176c024503317c |
publicationDate |
2014-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20140063911-A |
titleOfInvention |
The double-stranded ribonucleic acid which inhibits the expression of the Eg5 gene |
abstract |
The present invention relates to a method for inhibiting the expression of the Eg5 gene, comprising an antisense strand of less than 30 nucleotides in length, generally 19 to 25 nucleotides in length and having a nucleotide sequence substantially complementary to at least a portion of the Eg5 gene (DsRNA). ≪ / RTI > The invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a dsRNA; A method for treating a disease caused by the expression of Eg5 expression and Eg5 gene using the pharmaceutical composition; And a method for inhibiting the expression of an Eg5 gene in a cell. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190069245-A |
priorityDate |
2006-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |